Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.

• DOI: 10.1200/jco.2010.28.15_suppl.4612
• Publication Date: 2017-02-24T02:41:10Z
• Authors: G. H. Mickisch; B. Schwander; B. J. Escudier; J. Bellmunt; J. P. Maroto; C. Porta; S. Walzer; M. Nuijten
• Keywords: 01 natural sciences; 3. Good health; 0104 chemical sciences

4612 Background: There are currently three licensed first-line metastatic renal cell carcinoma (mRCC) targeted therapies, allowing the therapy of a broad first-line mRCC population with good or int...